PharmaShots | Incisive News in 3 Shots

Subscribe Now

Coherus Biosciences

Coherus BioSciences Features Preclinical Results of CHS-1000 for Solid Tumors at the AACR 2024

Coherus BioSciences Features Preclinical Results of CHS-1000 for Solid Tumors at the AACR 2024

April 9, 2024

Coherus BioSciences Launches an On Body Injector for the Administration of Udenyca (biosimiolar, pegfilgrastim) to Treat Non-Myeloid Malignancies

Coherus BioSciences Launches an On Body Injector for the Administration of Udenyca (biosimiolar, pegfilgrastim) to Treat Non-Myelo...

February 21, 2024

Coherus BioSciences to Divest its Ophthalmology Franchise to Sandoz for $170M Up Front

Coherus BioSciences to Divest its Ophthalmology Franchise to Sandoz for $170M Up Front

January 23, 2024

Coherus BioSciences Reports the Launch of Loqtorzi (toripalimab-tpzi) across the United States to Treat Nasopharyngeal Carcinoma (NPC)

Coherus BioSciences Reports the Launch of Loqtorzi (toripalimab-tpzi) across the United States to Treat Nasopharyngeal Carcinoma (...

January 3, 2024

Coherus BioSciences to Acquire Surface Oncology for ~$65M

Coherus BioSciences to Acquire Surface Oncology for ~$65M

June 19, 2023

Coherus BioSciences Reports the Pooled Analysis of Udenyca (biosimilar, pegfilgrastim) Demonstrated Similar Immunogenicity to Neulasta

Coherus BioSciences Reports the Pooled Analysis of Udenyca (biosimilar, pegfilgrastim) Demonstrated Similar Immunogenicity to Neul...

February 1, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us